



MANGALAM DRUGS & ORGANICS LTD.

Un-Audited Financial Results for the Quarter ended 30th June 2016 approved and taken on record by the Board at their meeting dated 01st August 2016

(Rs. in Lacs)

Sr. No.	Particulars	3 Months ended 30.06.2016 (Unaudited)	Corresponding 3 months ended 30.06.2015 (Unaudited)	3 Months ended 31.03.2016 (Audited)	Year Ended 31.03.2016 (Audited)
A PART I - STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2016					
1	Sales/Income from operation(Net of Excise duty)	6697.20	6956.09	7055.06	29502.18
2	Other Operating Income	1.30	2.72	11.17	13.89
3	Total Net Income from Operation	6698.50	6958.81	7066.23	29516.07
4	Expenditure				
	(a) Increase / decrease in stock in trade & work in progress	674.81	751.76	(417.77)	(7.95)
	(b) Consumption of raw materials	3756.19	4376.72	4461.42	20185.07
	(c) Employees Cost	402.87	304.75	410.23	1434.87
	(d) Depreciation	96.69	108.25	108.62	441.30
	(e) Other expenditure	833.54	880.23	1177.55	4134.02
	(f) Total	5764.10	6421.71	5740.05	26187.31
5	Profit(+)/Loss(-) from operations before Other income, Finance cost and Exceptional Items(3-4)	934.40	537.10	1326.18	3328.76
6	Other income	0.82	70.55	(72.41)	2.02
7	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items(5+6)	935.22	607.65	1253.77	3330.78
8	Finance Cost	229.97	232.39	277.03	929.18
9	Profit(+)/Loss(-) from ordinary activities after Finance cost & Exceptional Items(7-8)	705.25	375.26	976.74	2401.60
10	Exceptional Items	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) before Tax (9-10)	705.25	375.26	976.74	2401.60
12	Tax Expenses(incl Deferred Tax)	195.00	70.00	423.29	798.29
13	Net Profit(+)/Loss(-) after Tax (11-12)	510.25	305.26	553.45	1603.31
14	Extraordinary Items	0.00	0.00	0.00	0.00
15	Net Profit(+)/Loss(-) for the period(13-14)	510.25	305.26	553.45	1603.31
16	Paid up Equity Share Capital (face value Rs.10/-each)	1582.82	1317.82	1437.82	1437.82
17	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	0.00	0.00	3897.44	3897.44
18 (i)	Earning per share (EPS)(before extraordinary items)(of Rs 10/-each)(not annualised)				
	(a) Basic	3.22	2.32	3.85	11.15
	(b) Diluted	3.22	2.32	3.50	10.13
18 (ii)	Earning per share (EPS)(after extraordinary items)(of Rs 10/-each)(not annualised)				
	(a) Basic	3.22	2.32	3.85	11.15
	(b) Diluted	3.22	2.32	3.50	10.13
16	Investors Complaints :	3 Months ended 30.06.2016			
	Pending at the Beginning of the Quarter	Nil			
	Received during the Quarter	Nil			
	Disposed of during the Quarter	Nil			
	Remaining unresolved at the end of the Quarter	Nil			

Notes:

- 1 The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 1st August, 2016
- 2 The above results have been subjected to limited review by Statutory Auditors.
- 3 14,50,000 Equity shares are allotted on 10/06/2016 pursuant to conversion of 14,50,000 Share Warrants which were allotted on 28/09/2015.
- 4 As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk Drugs" the disclosure requirements of Accounting Standard(AS-17) "Segment Reporting" is not applicable
- 5 The CEO & CFO have certified that the Un-audited Financial Results for the Quarter ended 30th June 2016 do not contain any false or misleading statements or figures and do not omit any material facts which may make the statements or figures therein misleading.
- 6 Previous year figures are regrouped wherever necessary.

Place: Mumbai

Date: 01.08.2016

On behalf of Board of Directors

For Mangalam Drugs & Organics Ltd

(Shri Govardhan M.Dhoot)
Managing Director
DIN:01240086